ATAI vs AXSM
ATAI: Atai Beckley is a clinical-stage biotech firm developing novel treatments for central nervous system disorders. AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders.
Side-by-side fundamentals
| Metric | ATAI | AXSM | Edge |
|---|---|---|---|
| Price | $7.35 | $159.58 | |
| Market cap | $2.7B | $8.4B | |
| Net margin FY2025, SEC XBRL | -16142.0% | -28.7% | AXSM higher |
| Operating margin FY2025, SEC XBRL | -15751.1% | -26.1% | AXSM higher |
| ROE FY2025, SEC XBRL | -297.5% | -207.5% | AXSM higher |
| ROA FY2025, SEC XBRL | -225.5% | -26.6% | AXSM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.13 | 2.26 | ATAI lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +1227.6% | +65.5% | ATAI higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +133.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 1.39 | 0.66 | |
| 1-year return | +59.8% | +21.3% | ATAI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.